adalimumab ^Turanci (Q348260)

Daga Wikidata

Jump to navigation Jump to search

pharmaceutical drug ^Turanci

Language	Label	Description	Also known as
Hausa	Ba suna a kai	Ba'a bayyana ma'ana ba
Turanci	adalimumab	pharmaceutical drug	D2E7 Ig gamma-1 chain C region LU-200134 FKB327 Humira® Humira

Statements

type of chemical entity ^Turanci

0 references

Ƙaramin ɓangare na

chemical compound ^Turanci

0 references

1 reference

Adalimumab (Turanci)

stated in ^Turanci

DrugBank ^Turanci

harshen aiki ko suna

17 Nuwamba 2015

DrugBank ID ^Turanci

tsarin sinadaran

Adalimumab structure.svg
726 × 648; 5 KB

0 references

defined daily dose ^Turanci

2.9 milligram

route of administration ^Turanci

parenteral route of administration ^Turanci

1 reference

adireshin manazarta

https://www.whocc.no/atc_ddd_index/?code=L04AB04

active ingredient in ^Turanci

Humira ^Turanci

1 reference

European Medicines Agency product number ^Turanci

EMEA/H/C/000481

adireshin manazarta

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/human_med_000822.jsp

retrieved ^Turanci

22 Maris 2017

Trudexa ^Turanci

1 reference

European Medicines Agency product number ^Turanci

EMEA/H/C/000482

adireshin manazarta

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000482/human_med_001112.jsp

retrieved ^Turanci

22 Maris 2017

World Health Organisation international non-proprietary name ^Turanci

adalimumab (Turanci)

1 reference

stated in ^Turanci

ChEMBL ^Turanci

ChEMBL ID ^Turanci

harshen aiki ko suna

Adalimumab (Turanci)

retrieved ^Turanci

19 Janairu 2016

medical condition treated ^Turanci

Rheumatoid amosanin gabbai

1 reference

stated in ^Turanci

NDF-RT ^Turanci

NDF-RT ID ^Turanci

harshen aiki ko suna

retrieved ^Turanci

13 Disamba 2016

polyarthritis ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

pyoderma gangrenosum ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

osteoarthritis susceptibility 1 ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

pityriasis rubra pilaris ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

ankylosing spondylitis ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

colitis ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

iritis ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

arthropathy ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

reactive arthritis ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

granuloma annulare ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

Sjögren's syndrome ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

arthritis ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

Ulcerative colitis

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

Behçet's disease ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

uveitis ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

guttate psoriasis ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

irritable bowel syndrome ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

spondylitis ^Turanci

1 reference

stated in ^Turanci

Drug Indications Extracted from FAERS ^Turanci

retrieved ^Turanci

2 Oktoba 2018

legal status (medicine) ^Turanci

boxed warning ^Turanci

1 reference

adireshin manazarta

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (Turanci)

pregnancy category ^Turanci

Australian pregnancy category C ^Turanci

1 reference

English Wikipedia ^Turanci

US pregnancy category B ^Turanci

1 reference

English Wikipedia ^Turanci

LiverTox likelihood score ^Turanci

LiverTox toxicity likelihood category B ^Turanci

1 reference

stated in ^Turanci

LiverTox ^Turanci

retrieved ^Turanci

8 Afirilu 2021

adireshin manazarta

https://www.ncbi.nlm.nih.gov/books/n/livertox/Adalimumab

last update ^Turanci

10 Faburairu 2017

has characteristic ^Turanci

biopharmaceutical ^Turanci

1 reference

Adalimumab (Turanci)

stated in ^Turanci

DrugBank ^Turanci

harshen aiki ko suna

17 Nuwamba 2015

DrugBank ID ^Turanci

subject has role ^Turanci

immunologic factor ^Turanci

1 reference

stated in ^Turanci

NDF-RT ^Turanci

NDF-RT ID ^Turanci

retrieved ^Turanci

5 Maris 2018

disease-modifying antirheumatic drug ^Turanci

1 reference

stated in ^Turanci

Medical Subject Headings ^Turanci

MeSH descriptor ID ^Turanci

retrieved ^Turanci

15 Maris 2018

anti-inflammatory agent ^Turanci

1 reference

stated in ^Turanci

Medical Subject Headings ^Turanci

MeSH descriptor ID ^Turanci

retrieved ^Turanci

15 Maris 2018

monoclonal antibody ^Turanci

2 references

stated in ^Turanci

DrugBank ^Turanci

DrugBank ID ^Turanci

harshen aiki ko suna

Adalimumab (Turanci)

17 Nuwamba 2015

stated in ^Turanci

NDF-RT ^Turanci

NDF-RT ID ^Turanci

retrieved ^Turanci

27 Faburairu 2018

related image ^Turanci

Autoinjector with Amgevita by Amgen (Adalimumab)-6390.jpg
4,181 × 2,352; 3.29 MB

0 references

Commons category ^Turanci

Adalimumab

0 references

Identifiers

CAS Registry Number ^Turanci

1 reference

stated in ^Turanci

DrugBank ^Turanci

DrugBank ID ^Turanci

harshen aiki ko suna

Adalimumab (Turanci)

17 Nuwamba 2015

ChEMBL ID ^Turanci

1 reference

stated in ^Turanci

ChEMBL ^Turanci

ChEMBL ID ^Turanci

harshen aiki ko suna

Adalimumab (Turanci)

retrieved ^Turanci

19 Janairu 2016

HSDB ID ^Turanci

1 reference

stated in ^Turanci

Hazardous Substances Data Bank ^Turanci

HSDB ID ^Turanci

28 Oktoba 2019

Adalimumab (Turanci)

retrieved ^Turanci

10 Mayu 2021

LiverTox ID ^Turanci

0 references

EC number ^Turanci

695-701-7

1 reference

stated in ^Turanci

ECHA Substance Infocard database ^Turanci

ECHA Substance Infocard ID ^Turanci

retrieved ^Turanci

27 Disamba 2018

Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer (Turanci)

quotation ^Turanci

CAS no.: 331731-18-1 (Turanci)

ECHA Substance Infocard ID ^Turanci

1 reference

stated in ^Turanci

ECHA Substance Infocard database ^Turanci

ECHA Substance Infocard ID ^Turanci

retrieved ^Turanci

27 Disamba 2018

Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer (Turanci)

quotation ^Turanci

CAS no.: 331731-18-1 (Turanci)

1 reference

stated in ^Turanci

DrugBank ^Turanci

DrugBank ID ^Turanci

harshen aiki ko suna

Adalimumab (Turanci)

17 Nuwamba 2015

World Health Organisation international non-proprietary name numeric ID ^Turanci

0 references

Guide to Pharmacology Ligand ID ^Turanci

0 references

MeSH descriptor ID ^Turanci

subject named as ^Turanci

Adalimumab

0 references

Lambar itace MeSH

D12.776.124.486.485.114.224.060.250

0 references

D12.776.124.790.651.114.224.060.250

0 references

D12.776.377.715.548.114.224.200.250

0 references

RxNorm ID ^Turanci

1 reference

stated in ^Turanci

NDF-RT ^Turanci

NDF-RT ID ^Turanci

retrieved ^Turanci

26 Faburairu 2018

DrugBank ID ^Turanci

0 references

UNII ^Turanci

1 reference

stated in ^Turanci

NDF-RT ^Turanci

NDF-RT ID ^Turanci

harshen aiki ko suna

ADALIMUMAB (Turanci)

retrieved ^Turanci

19 Janairu 2016

MedlinePlus drug identifier ^Turanci

0 references

PatientsLikeMe treatment ID ^Turanci

0 references

NDF-RT ID ^Turanci

1 reference

stated in ^Turanci

NDF-RT ^Turanci

NDF-RT ID ^Turanci

harshen aiki ko suna

ADALIMUMAB (Turanci)

retrieved ^Turanci

19 Janairu 2016

KEGG ID ^Turanci

1 reference

English Wikipedia ^Turanci

CAB ID ^Turanci

1 reference

stated in ^Turanci

CAB Thesaurus ^Turanci

retrieved ^Turanci

6 Afirilu 2020

DeCS ID ^Turanci

0 references

electronic Essential Medicines List medicine ID ^Turanci

0 references

Freebase ID ^Turanci

1 reference

stated in ^Turanci

Freebase Data Dumps ^Turanci

28 Oktoba 2013

Microsoft Academic ID ^Turanci

0 references

OpenAlex ID ^Turanci

1 reference

stated in ^Turanci

OpenAlex ^Turanci

retrieved ^Turanci

26 Janairu 2022

adireshin manazarta

https://docs.openalex.org/download-snapshot/snapshot-data-format

Quora topic ID ^Turanci

1 reference

stated in ^Turanci

ScienceDirect topic ID ^Turanci

agricultural-and-biological-sciences/adalimumab

0 references

UMLS CUI ^Turanci

1 reference

based on heuristic ^Turanci

inferred by common MeSH mappings on source and on Wikidata ^Turanci

stated in ^Turanci

UMLS 2023 ^Turanci

retrieved ^Turanci

25 Mayu 2023

WikiProjectMed ID ^Turanci

0 references

Sitelinks

Wikipedia(28 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Wasu shafuka(1 entry)

commonswiki Category:Adalimumab

Daga "https://www.wikidata.org/w/index.php?title=Q348260&oldid=2190009903"